NeuroSense Therapeutics Ltd. (NRSN)

NASDAQ: NRSN · IEX Real-Time Price · USD

0.732

-0.029 (-3.76%)

At close: Jul 19, 2024, 4:00 PM

0.800

+0.068 (9.35%)

Pre-market: Jul 22, 2024, 8:00 AM EDT

NeuroSense Therapeutics Employees

NeuroSense Therapeutics had 18 employees as of December 31, 2023. The number of employees increased by 4 or 28.57% compared to the previous year.

Employees

18

Change (1Y)

4

Growth (1Y)

28.57%

Revenue / Employee

n/a

Profits / Employee

-$561,500

Market Cap

13.20M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2023	18	4	28.57%
Dec 31, 2022	14	3	27.27%
Dec 31, 2021	11	-	-

Related Stocks

Company Name	Employees
Universe Pharmaceuticals INC	225
Psychemedics	116
Addex Therapeutics	23
Purple Biotech	20
Avalo Therapeutics	19
NEXGEL	19
GeoVax Labs	17
QT Imaging Holdings	14

Employee Rankings

NRSN News

12 days ago - NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression - PRNewsWire
19 days ago - This cheap biotech offers investors a play on ALS if trial data continues to impress - Market Watch
21 days ago - NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug - PRNewsWire
27 days ago - NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results - PRNewsWire
4 weeks ago - NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal - PRNewsWire
2 months ago - NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - PRNewsWire
2 months ago - NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - PRNewsWire
2 months ago - NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients - PRNewsWire